Skip to main content

Blood Donation; a Risk for Prenatal Developmental Toxicity?

  • Chapter
Transmissible Diseases and Blood Transfusion

Part of the book series: Developments in Hematology and Immunology ((DIHI,volume 37))

  • 135 Accesses

Abstract

Most prescribers and users of drugs are familiar with the cautions on drug use during the first trimester of pregnancy. These warnings were introduced after the thalidomide disaster in the early 1960s. However, limiting the exercise of caution to the first 3 months of pregnancy is both short sighted and effectively impossible. First, because chemicals can affect any stage of pre- or postnatal development, and second, because when a woman first learns that she is pregnant, the process of organogenesis has already long since begun, for example, the neural walls are closed. In the case of blood donations there exists a possibility that medicinal products, prescribed to donors or used by them as “over the counter” drugs can become available in the recipients of blood donations. Hence, it is interesting not only to focus on blood donation as such but also to discuss here in general the developmental toxicity of biologically active substances and especially medicinal products. Blood donation is in this context then a special route of exposure. This text will present the current state of knowledge about the (un)safety of the use of medicinal products, including those that might be presented by blood donation in pregnancy. One must realise that to my knowledge there exists no literature or other data showing such hazard and risk. However, biological active substances might be transferred by blood donation into recipients. Hence, it will be important to understand the main issues in the field of reproductive and developmental toxicology. A recent guide about the safety of use of drugs during pregnancy and lactation is edited by Schaefer [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schaefer Chr. ed. Drugs during pregnancy and lactation, Amsterdam, Elsevier, 2001.

    Google Scholar 

  2. Chamberlain G. Organisation of antenatal care. BMJ 1991; 302: 647.

    Article  PubMed  CAS  Google Scholar 

  3. Warkany J, Nelson RC. Appearance of skeletal abnormalities in the offspring of rats retarded on a deficient diet. Science 1940; 92: 383–84.

    Article  PubMed  CAS  Google Scholar 

  4. Barker DJP. Mothers, babies and health in later life. Churchill Livingston, Edinburgh 1998, 2nd edition.

    Google Scholar 

  5. Hale F. Pigs born without eyeballs. J Hered 1933; 24: 105–06.

    Google Scholar 

  6. Gregg NM. Congenital cataract following German measles in mother. Trans Ophthalmol Soc Aust 1941; 3: 35–46.

    Google Scholar 

  7. Lenz W. Kindliche Fehlbildungen nach Medikament während der Gravidität? Dtsch Med Wochenschr 1961; 86: 2555–56.

    Google Scholar 

  8. Wilson JD. Embryotoxicity of drugs to man. In: Handbook of teratology, Vol. 1. Wilson JD, Frazer FC, eds.. New York, Plenum Press, 1977; 309–55.

    Google Scholar 

  9. Committee on Dev. Toxicol. NAS/NRC. Scientific Frontiers in Developmental Toxicology and Risk Assessment. National Research Council, Washington DC 2000; 10–25.

    Google Scholar 

  10. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997; 33: 328–43.

    Article  PubMed  CAS  Google Scholar 

  11. Lander CM, Smith MT, Chalk JB et al. Bioavailability in pharmacokinetics of phenytoin during pregnancy. Eur J Clin Pharmacol 1984; 27: 105–10.

    PubMed  CAS  Google Scholar 

  12. Juchau MR. Bioactivation in chemical teratogenesis. Ann Rev Pharmacol Toxicol 1989; 29: 165–87.

    Article  CAS  Google Scholar 

  13. Schardein JL. Chemically induced birth defects. New York, Marcel Dekker, 2000, 4th edition.

    Google Scholar 

  14. Enders G. Infektionen und Impfungen in der Schwangerschaft. München, Urban & Schwarzenberg, 1991, 2nd edition.

    Google Scholar 

  15. Nelson K, Holmes LB. Malformations due to presumed spontaneous mutations in newborn infants. N Engl J Med 1989; 320: 19–23.

    Article  PubMed  CAS  Google Scholar 

  16. Shepard TH. Letter: “proof” of teratogenicity. Teratology 1994; 50: 97.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Peters, P.W.J. (2002). Blood Donation; a Risk for Prenatal Developmental Toxicity?. In: Sibinga, C.T.S., Dodd, R.Y. (eds) Transmissible Diseases and Blood Transfusion. Developments in Hematology and Immunology, vol 37. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6869-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-6869-5_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-5233-2

  • Online ISBN: 978-1-4757-6869-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics